Haisco's self-developed oral small-molecule pain drug HSK51155 tablets have received clinical trial approval from the National Medical Products Administration. The drug is intended for the treatment of migraines and is expected to control pain while reducing adverse reactions and avoiding the risk of addiction. Previously, in April 2026, Haisco entered into a cooperation agreement with AbbVie Group Holdings Ltd., granting AbbVie exclusive rights to develop, manufacture, and commercialize the drug globally outside of mainland China, Hong Kong, and Macau, with a potential total transaction value exceeding 700 million US dollars. In the first quarter of 2026, Haisco achieved revenue of 1.564 billion yuan and net profit attributable to the parent company of 555 million yuan.
AbbVie IncAbbVie has exclusive global rights to develop and commercialize HSK51155, a promising migraine drug with potential deal value over $700M.
Xizang Haisco Pharmaceutical Group Co LtdHaisco's drug HSK51155 received clinical trial approval, advancing its pipeline and validating its partnership with AbbVie.
